coinbase teasing a big announcement today
imo they will discontinue their perps platform
and relaunch it using hyperliquid builder codes
this is the obvious correct path for them - they should focus on being a brokerage business
their 'expertise' is distribution + the client relationship
the aqav2 deal btwn crcl / coinbase and hyperliquid made me sure this would happen eventually
when it does $hype is teleporting to $100+
lets see if its today 🫡
$coin $crcl $hype
截止发帖时间,rpow社区捐赠地址已收到31552个srpow.
查询:
https://t.co/OcqVcbTj1V
感谢热心的rpow fam。
目前,我们正在整理空投的方式,本周就会出细节。请放心,我们将确保每一个 rpow都空投给真实的新用户。
加入电报:
https://t.co/N1vYhcOoVC
As of the time of posting, the RPOW community donation address has received 31,552 sRPOW.
Check it here:
https://t.co/OcqVcbTj1V
A huge thank-you to all the generous RPOW fam who contributed.
We are currently finalizing the airdrop distribution plan, and full details will be announced later this week. Rest assured, we will make every effort to ensure that every RPOW is airdropped to genuine new users.
Join our Telegram community:
https://t.co/N1vYhcOoVC
A machine learning professor at Carnegie Mellon spends his days writing mathematical proofs about why deep learning works at all. He has no Twitter following. He runs no startup. He gives no TED talks. He has never been on a podcast.
He has won one of the most prestigious early-career awards in American academic science and trained a generation of researchers who now work at OpenAI, Google, MIT, and Stanford. Most people scrolling AI Twitter have never heard his name.
His name is Andrej Risteski.
Here is the story, because the theoretical foundations of modern AI are being written by people the industry rarely talks about.
Andrej did his PhD at Princeton in the Computer Science department under Sanjeev Arora. To anyone outside the theoretical ML world this name means little. Inside it, Arora is one of the most influential theoretical computer scientists alive. He runs the theoretical foundations of deep learning group at Princeton. He is the closest thing the field has to a school of thought, and Andrej trained directly inside it.
After Princeton, Andrej moved to MIT as a Norbert Wiener Research Fellow, a position jointly held in the Applied Mathematics department and the Institute for Data, Systems, and Society. The Wiener Fellowship is one of the rare postdoctoral positions in the United States explicitly created for researchers working at the intersection of mathematics and machine learning. The math department does not give these out lightly.
He joined Carnegie Mellon as an Assistant Professor in the Machine Learning Department. He has since been promoted to Associate Professor. His research focuses on the questions nobody writes viral threads about. Why do generative models work. Why does self-supervised learning produce useful representations. When does out-of-distribution generalization actually happen. What are the mathematical guarantees underneath the systems the industry shipped to a billion people without proving anything formal about.
The work is dense. The papers have titles most engineers would skip. Provable Benefits of Score Matching. Sampling from Energy-Based Models with Score Matching. Theory of Self-Supervised Learning Through the Lens of Probabilistic Generative Models. The kind of papers that get cited heavily inside academia and almost never get a Twitter moment.
He has won the NSF CAREER Award, an extremely competitive grant given annually to a small group of early-career US scientists deemed most likely to shape their field. The award itself comes with around half a million dollars in research funding over five years. His specific grant is titled "Theoretical Foundations of Modern Machine Learning Paradigms: Generative and Out-of-Distribution." He has also won an Amazon Research Award for work on causal and out-of-distribution learning. He is supported by additional NSF awards for foundational work on self-supervised learning.
His collaborators are a who's-who of theoretical machine learning. Ankur Moitra at MIT. Rong Ge at Duke. Holden Lee at Johns Hopkins. Frederic Koehler at UChicago. Yu Bai at OpenAI. Pranjal Awasthi at Google. Moses Charikar at Stanford. Yoon Kim at MIT. The same names appear on his Google Scholar co-author list year after year. These are the people writing the theorems the industry is starting to rediscover when its models break in production.
Andrej runs the Modern Paradigms in Generalization program at the Simons Institute at Berkeley as a visiting scientist. He has been there twice, once in 2021 on Computational Complexity of Statistical Inference, and again in 2024. The Simons Institute is the premier venue in the world for theoretical computer science. Most people who get invited once never get invited back.
He does not have a public profile in the way the industry usually defines one. His personal website at andrejristeski .org is a flat page with no styling. His Google Scholar page lists papers. His CMU page lists an office number and an email. That is all.
A Princeton-trained mathematician at Carnegie Mellon is quietly writing the theorems that explain why the most expensive systems in technology actually work.
He just is not online about it.
Solana's apps are moving before $SOL does.
Jupiter's aggregator volume is up 238% over the past 30 days. Orca's DEX volume is up 20%.
Most of CT is still waiting for “Solana season,” but the infra layers are already waking up.
Here’s why they’ve gone higher:
- Jupiter did $18.3B in aggregator volume over the last 30 days and remains the default routing layer for Solana swaps
- Orca is gaining share while a lot of DEX activity elsewhere is flat or down
- $PUMP still generated $26.4M in fees in a boring market
- @Raydium did $4.3B in DEX volume and remains the default listing venue for new Solana tokens
None of this looks like peak-cycle activity.
Here’s why it goes higher:
- A real Solana szn sends more flow through Jupiter
- More token launches mean more volume for Raydium
- More speculation means more activity through $PUMP
- Orca is still under the radar despite growing volume and fee capture
The valuation for these tokens is the most interesting part.
$PUMP trades $537M mcap with a $316M annualized fee run rate.
$ORCA trades at $70 M mcap with a $41M annualized fee run rate.
$ORCA to $6.75 is a $411M mcap coin. That is only 10x its annualized fee run rate.
The same re-rate scenario puts $JUP around $0.59.
Everyone is waiting for $SOL to move, yet the apps are already moving.
2026년 기준 실수령액 현실
1️⃣ 연봉 2,500만원 → 월 약 185만원
2️⃣ 연봉 3,000만원 → 월 약 218만원
3️⃣ 연봉 3,500만원 → 월 약 251만원
4️⃣ 연봉 4,000만원 → 월 약 284만원
5️⃣ 연봉 4,500만원 → 월 약 315만원
6️⃣ 연봉 5,000만원 → 월 약 344만원
7️⃣ 연봉 5,500만원 → 월 약 371만원
8️⃣ 연봉 6,000만원 → 월 약 397만원
9️⃣ 연봉 6,500만원 → 월 약 422만원
🔟 연봉 7,000만원 → 월 약 446만원
1️⃣1️⃣ 연봉 7,500만원 → 월 약 469만원
1️⃣2️⃣ 연봉 8,000만원 → 월 약491만원
1️⃣3️⃣ 연봉 8,500만원 → 월 약 513만원
1️⃣4️⃣ 연봉 9,000만원 → 월 약 534만원
1️⃣5️⃣ 연봉 9,500만원 → 월 약 554만원
1️⃣6️⃣ 연봉 1억원 → 월 약 574만원
연봉 1억 받아도
세금 떼면 월 574만원
blackrock's BITA launches june 18. covered call ETF on bitcoin. 0.65% fee, undercuts every competitor. here's the thing: YBTC runs the same strategy and is down 45% over 12 months while BTC is only down 14%. 91-96% of distributions across existing bitcoin income ETFs are return of capital. investors literally receiving their own money back labeled as yield. BITA will probably do the same. but every dollar into BITA buys spot BTC or IBIT shares. blackrock is building a $36B JEPI-style demand funnel for bitcoin disguised as an income product. the holders will underperform. the asset won't care. it just absorbs the flow.
Space X is trading at 105x trailing revenues.
For context, NVDA is at 25x, TSLA is at 17x and the SP500 is at 3.5x
The "normalized earnings" ratio would put it at 250x earnings.
Tradfi is telling you to buy that, and sell BTC at 0.45x power law.
Why is nobody talking about this drug that $NVO is about to launch?
Novo Nordisk has already filed a New Drug Application (NDA) for Icosema, a diabetes drug that combines basal insulin with their proven semaglutide product. They're targeting severe type 2 diabetes patients who have progressed to the point of needing insulin injections.
Standard semaglutide, tirzepatide, and retatrutide is NOT the same as insulin. Diabetics who need insulin may be taking one of those drugs AND a daily insulin shot. Icosema combines those into one weekly injection, improving convenience for the customer and lowering the amount of injections by eight times.
There is no comparable drug on the market right now.
$NVO $LLY
Waiting list for wegovy pill in UK is expected to be about 100,000…….
I don’t know if this is true. But if it is then it will be a spectacular launch. And hitting 250,000 during Q3 seems possible.
That kind of interest would also mean everyone would have to redo their models for wegovy pill sales significantly.
But all this is still spekulative. Let’s see how the actual launch will go. Telehealth likely starting deliveries in about 1 week. And then it will take 1-2 weeks more before all pharmacies has received their supply
$LLY $NVO $VKTX
Today’s hottest Crypto Twitter sentiment: BTC is chopping around $61K-$63K, AI/tech stocks are pulling back, the SpaceX IPO is draining liquidity, and the market is shifting back into risk-off mode.
But RPOW2’s narrative is becoming even clearer: it won’t survive cycles through hype alone, but through PoW, fair participation, SRPOW/Solana, tipping, DEX infrastructure, and real usage.
Current public ledger: 14.2M+ minted, 29-bit difficulty, 290K+ users.
Liquidity rotates. Attention fades. Networks that can be verified and used are the ones that keep growing.
今天 Crypto Twitter 最热的情绪:BTC 在 6.1-6.3 万附近拉扯,AI/科技股回撤,SpaceX IPO 抽流动性,市场又回到 risk-off。
但 RPOW2 的叙事反而更清楚了:不是靠喊单穿越周期,而是靠 PoW、公平参与、SRPOW/Solana、tip、DEX 和真实使用率留下来。
当前公开账本:1420 万+ minted,29 bits 难度,29 万+ 用户。
流动性会轮动,注意力会退潮,能被验证和使用的网络才会继续生长。
加入电报群:
https://t.co/N1vYhcOoVC
购买:
https://t.co/TPmEPL60g3
🚨 FDA PUTS FOUNDAYO UNDER POST MARKETING MICROSCOPE:
Among other things… DILI.
Yes, drug induced liver injury, the exact risk we’ve been flagging with orforglipron from the start.
FDA isn’t just watching mild enzyme bumps, they’re demanding full Hy’s Law level tracking, case level reporting, and discontinuations tied to liver signals.
Pretty interesting given this was one of the fastest FDA drug approvals in history.
$LLY $NVO